ストックスクリーナーアプリを入手
0.6781
2.85%
-0.0199
Lexaria Bioscience Corp (LEXX) 最新ニュース
Why Lexaria Bioscience Corp. Equity Warrant stock could be next big winnerJuly 2025 Macro Moves & Verified Chart Pattern Trade Signals - ulpravda.ru
Growth Value: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainable2025 Key Lessons & Technical Pattern Based Buy Signals - moha.gov.vn
Lexaria Bioscience (LEXX) Expected to Announce Earnings on Friday - Defense World
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - New Castle News
Lexaria releases additional results from Phase 1b study GLP-1-H24-4 - Yahoo Finance
Lexaria’s Phase 1b GLP-1 Study Shows Comparable Metabolic Outcomes and Encouraging Blood Pressure Data for DehydraTECH Platform - TipRanks
Lexaria Bioscience (LEXX) Reports Promising Results from Phase 1 - GuruFocus
Drug trial in overweight patients ties CBD formula to lower blood pressure - Stock Titan
Lexaria Bioscience (NASDAQ:LEXX) Shares Up 5.5% – Here’s What Happened - Defense World
Sentiment Review: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainableMarket Performance Report & Stepwise Trade Execution Plans - moha.gov.vn
How geopolitical tensions affect Lexaria Bioscience Corp stock2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn
Lexaria Bioscience secures $3.5 million in direct offering to boost R&D - MSN
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN
Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright By Investing.com - Investing.com South Africa
Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright - Investing.com
LEXX: HC Wainwright & Co. Lowers Price Target to $1.50, Maintains Buy Rating | LEXX Stock News - GuruFocus
LEXX: DehydraTECH Formulation Reduces GLP-1 Agonist Side Effects - Research Tree
Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - York Dispatch
Lexaria’s DehydraTECH-semaglutide cuts GLP-1 side effects in phase 1b trial and extends cash runway into 2026 - MSN
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga
Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026 - TipRanks
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 - Investing News Network
Experimental oral GLP-1 pill cuts side effects by nearly half in trial - Stock Titan
Is Lexaria Bioscience Corp. stock resilient to inflationJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - Улправда
What momentum indicators show for Lexaria Bioscience Corp. stockPortfolio Growth Summary & AI Powered Market Trend Analysis - Улправда
Will Lexaria Bioscience Corp. stock deliver better than expected guidanceQuarterly Profit Review & Safe Capital Investment Plans - Улправда
Is Lexaria Bioscience Corp. stock a buy on dipsJuly 2025 Technicals & AI Optimized Trading Strategy Guides - Улправда
Portfolio Recap: What valuation multiples suggest for Lexaria Bioscience Corp. Equity Warrant stockBreakout Watch & Fast Entry and Exit Trade Plans - Улправда
Setup Watch: Is Lexaria Bioscience Corp. stock resilient to inflationSell Signal & Consistent Profit Trade Alerts - Улправда
How geopolitical tensions affect Lexaria Bioscience Corp. stockJuly 2025 Short Interest & Free Expert Verified Stock Movement Alerts - DonanımHaber
Will Lexaria Bioscience Corp. Equity Warrant stock benefit from AI adoptionWeekly Profit Summary & Risk Managed Trade Strategies - DonanımHaber
Published on: 2025-12-19 15:15:39 - DonanımHaber
Published on: 2025-12-19 14:32:21 - DonanımHaber
Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationWeekly Earnings Recap & Weekly Top Stock Performers List - Улправда
Momentum Shift: Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationJuly 2025 Breakouts & Daily Risk Controlled Trade Plans - Улправда
Lexaria Bioscience Corp (LEXX) is a good investment, but the stock may be undervalued - uspostnews.com
Lexaria Bioscience Corp. (LEXX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Lexaria Bioscience Secures $3.5 Million in Capital Through Registered Direct Offering - citybuzz -
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Investing News Network
Lexaria Bioscience closes $3.5 million registered direct offering - Investing.com
Lexaria Bioscience closes $3.5 million registered direct offering By Investing.com - Investing.com Canada
Lexaria Bioscience (NASDAQ: LEXX) details approximately $3.5 million financing terms - Stock Titan
5.77%
大文字化:
|
ボリューム (24 時間):